rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Amarin Corporation plc - American Depositary Shares

AMRN · Nasdaq

Health CareBiotechnologyNot moving yet

AMRN stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 46 weeks. It is 19.0% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 46
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
80 (+19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders80+19 on the quarter
New · exited25 · 6
Reported value$62.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Sarissa Capital Management LPunchanged · filed 14 Aug 20261,673,395$26.7M00.0%
Kynam Capital Management, LPadded · filed 14 Aug 2026532,982$8.5M+60,600+12.8%
MORGAN STANLEYreduced · filed 13 Aug 2026223,617$3.6M-69,555−23.7%
Waterfront Wealth Inc.added · filed 30 Jul 2026213,949$3.2M+10,611+5.2%
Brooklands Fund Management Ltdnew · filed 11 Aug 2026177,325$2.7M+177,325
Eversept Partners, LPreduced · filed 14 Aug 2026145,296$2.3M-2,419−1.6%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026115,808$1.8M-184,728−61.5%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026100,511$1.6M-7,031−6.5%
CITADEL ADVISORS LLCadded · filed 14 Aug 202695,364$1.5M+14,789+18.4%
BNP PARIBAS FINANCIAL MARKETSreduced · filed 13 Aug 202671,813$1.1M-3,690−4.9%
31 Mar 2025 – 30 Jun 2026
114681Mar 25Jun 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Peter L. Fishman Company insiderSVP, CFO · last 1 Aug 20260 · 0
David Paul Keenan Company insiderEVP, Chief Operating Officer · last 1 Jul 20260 · 0
Jonathan Provoost Company insiderEVP, Chief Legal Officer · last 1 Jul 20260 · 0
Steven B. Ketchum Company insiderEVP, Chief Scientific Officer · last 1 Jul 20260 · 21
Aaron Berg Company insiderPresident and CEO · last 26 Jun 20261 · 4
Diane E. Sullivan Company insiderDirector · last 18 Apr 20260 · 0
Keith Horn Company insiderDirector · last 18 Apr 20260 · 0
Kostas D. Odysseas Company insiderDirector · last 18 Apr 20260 · 0
Louis Sterling III Company insiderDirector · last 18 Apr 20260 · 0
Oliver O'Connor Company insiderDirector · last 18 Apr 20260 · 0
Patrice Eadon Bonfiglio Company insiderDirector · last 18 Apr 20260 · 0
Paul Cohen Company insiderDirector · last 18 Apr 20260 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202556.6%
Operating profit marginFY 2025 · to 31 Dec 2025-23.5%
Return on capital employedFY 2025 · to 31 Dec 2025-10.5%
Research spendFY 2025 · to 31 Dec 20259.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$134.7M

Analyst forecasts

No analyst forecasts yet.